In the meantime, the WHO recommended it be used only in people who had a prior infection with dengue. Brazil, where dengue is a significant health challenge, had already recommended restricted use of the vaccine. While Sanofi’s Dengvaxia is the first approved vaccine for dengue, scientists already recognised it did not protect equally against the four different types of the virus. But for those not previously infected, more cases of severe disease could occur following vaccination, Sanofi said. There was no indication that Philippines health officials knew of any risks when they administered the vaccination.

Source: The Guardian December 05, 2017 03:45 UTC